Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Pfizer’s VYNDAQEL®/VYNDAMAX® Reduced the Risk of All-Cause Mortality by 41% Among Patients with Transthyretin Amyloid Cardiomyopathy, Five-Year Follow-Up Data Demonstratehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer’s VYNDAQEL®/VYNDAMAX® Reduced the Risk of All-Cause Mortality by 41% Among Patients with Transthyretin Amyloid Cardiomyopathy, Five-Year Follow-Up Data Demonstrate


Pfizer Inc. (NYSE: PFE) announced today the publication of a post-hoc, interim analysis showing that treatment with VYNDAQEL® (tafamidis meglumine) / VYNDAMAX® (tafamidis) provided a clinically

Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supplyhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supply


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement has been reached with the European Commission (EC) and its member states to exercise an option to purchase more

EMA Issues Advice for Potential Early Use of Pfizer’s Novel COVID-19 Oral Antiviral Candidatehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
EMA Issues Advice for Potential Early Use of Pfizer’s Novel COVID-19 Oral Antiviral Candidate


Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued advice on the use of PAXLOVID™ (nirmatrelvir

U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Ankylosing Spondylitishttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Ankylosing Spondylitis


Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for XELJANZ® / XELJANZ® XR (tofacitinib) for the

Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Deathhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death


Pfizer Inc. (NYSE: PFE) today announced final results from an analysis of all 2,246 adults enrolled in its Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients)

Pfizer to Acquire Arena Pharmaceuticalshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer to Acquire Arena Pharmaceuticals


Pfizer Inc. (NYSE: PFE) and Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical

Pfizer Declares First-Quarter 2022 Dividendhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Declares First-Quarter 2022 Dividend


Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company’s common stock to $0.40 for the first-quarter 2022 dividend

European Commission Approves Pfizer’s Cibinqo® (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
European Commission Approves Pfizer’s Cibinqo® (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis


Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved the 100 mg and 200 mg doses of Cibinqo® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Olderhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) of a booster dose of the

Pfizer and BioNTech Provide Update on Omicron Varianthttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech Provide Update on Omicron Variant


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an initial laboratory study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine

Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidatehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate


Pfizer Inc. (NYSE: PFE) invites investors and the general public to access a live webcast of a presentation and conference call with investment analysts at 8:30 a.m. EST on Friday, December 17

4 Dividend Aristocrats Trading at a Discounthttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
4 Dividend Aristocrats Trading at a Discount

The first quarter of the year was a success for investors. The overall market (NYSE: SPY) surged nearly 10%, fueled by robust economic indicators, optimism, and hype surrounding AI. The

Pfizer’s earnings growth trade at a deep discount, suddenly a buyhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer’s earnings growth trade at a deep discount, suddenly a buy

The defensive names, characterized by their immunity to the business cycle, in the market could soon see an inflow of investment dollars not seen since the last wave of the business cycle. This

MarketBeat Week in Review – 5/22 - 5/26http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
MarketBeat Week in Review – 5/22 - 5/26

Two competing stories are fighting for investors’ attention. The bulls are trying to push the market higher in expectations of a resolution to the debt ceiling standoff. But any excitement is being

Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report: https://www.marketbeat.com/logos/articles/med_20240505135039_chartszy-pfe.jpg
Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report

Biopharma giant Pfizer Inc. (NYSE: PFE) has given back all its COVID gains and more. Shareholders have sat through a painful two-year selloff from the stock's $61.71 high on December 20, 2021, to

Sensationelle Studienergebnisse - Hautkrebs vollständig geheilt. Neuer 797% Biotech Hot Stock nach 15.973% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). : https://www.irw-press.at/prcom/images/messages/2024/73886/AC-03-11-24_AC01.001.png
Sensationelle Studienergebnisse - Hautkrebs vollständig geheilt. Neuer 797% Biotech Hot Stock nach 15.973% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB).

Sensationelle Studienergebnisse - Hautkrebs vollständig geheilt. 797% Biotech Hot Stock nach 10.996% mit Pfizer ($PFE)

 

11.03.24 08:02

AC Research

 

London (www.aktiencheck.de, Anzeige)

 

 

Pfizer at 10-year support: Is it a massive buy opportunity?: https://www.marketbeat.com/logos/articles/med_20240212102305_pfizers-at-10-year-support-is-it-a-massive-buy-opp.jpg
Pfizer at 10-year support: Is it a massive buy opportunity?

For shareholders of the multinational biotech giant Pfizer Inc. (NYSE: PFE), it might feel like the stock's all-time highs set during the pandemic were centuries ago. After making its

Markets suddenly price Eli Lilly stock for a breakout on earnings: https://www.marketbeat.com/logos/articles/med_20240205101509_markets-suddenly-price-eli-lilly-stock-for-a-break.jpg
Markets suddenly price Eli Lilly stock for a breakout on earnings

Nowadays, the market sends mixed signals to virtually every investor attempting to participate today, squeezing out a few percentage points of gains from the stock movements. With the Federal

2 low-priced gene therapy stocks to speculate on: https://www.marketbeat.com/logos/articles/med_20240107112838_chart-sgmo.jpg
2 low-priced gene therapy stocks to speculate on

Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic differences. Gene-editing involves using

Align Technology: Protected by more factors than any other stock: https://www.marketbeat.com/logos/articles/med_20231226071503_align-technology-protected-by-more-factors-than-an.jpg
Align Technology: Protected by more factors than any other stock

Because the past few months in the stock market have been a wild emotional roller coaster, most investors are now looking for the most logical and fundamental reasons to justify investing in any

Pfizer's chaotic year wraps up with plunging stock, grim guidance: https://www.marketbeat.com/logos/articles/med_20231220201736_pfizers-chaotic-year-wraps-up-with-plunging-stock.jpg
Pfizer's chaotic year wraps up with plunging stock, grim guidance

Investors who own Pfizer Inc. (NYSE: PFE) may have expected 2023 to be what football teams call a "rebuilding year." The company shifted its focus away from COVID-19 drugs and toward potential

Quick list of bargain stocks to end the year: https://www.marketbeat.com/logos/articles/med_20231215043651_quick-list-of-bargain-stocks-to-end-the-year.jpg
Quick list of bargain stocks to end the year

Here's a quick economics lesson to return to the good old college days. When markets think that a country's GDP is set to grow in the future, they will turn bullish (massively bullish) toward

Simply Good Foods: Winner in the Ozempic Weight-Loss Trend: https://www.marketbeat.com/logos/articles/med_20231203163352_chart-smpl2.jpg
Simply Good Foods: Winner in the Ozempic Weight-Loss Trend

Nutritional food and snacks producer The Simply Good Foods Co. (NASDAQ: SMPL) has seen its shares rocket higher on the weight-loss medication trend led by Ozempic, Novo Nordisk A/S (NYSE: NVO)

Ozempic vs. Mounjaro:: Battle of the bulge: https://www.marketbeat.com/logos/articles/med_20231204090609_battle-of-the-bulge-ozempic-vs.jpg
Ozempic vs. Mounjaro:: Battle of the bulge

The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs in the medical sector, led by the popularity of Ozempic. Celebrity usage and social media exposure have caused

J&J, Gilead, BMS: A look at undervalued dividend payers: https://www.marketbeat.com/logos/articles/med_20231128191819_jj-gilead-bms-a-look-at-undervalued-dividend-payer.jpg